Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.50 |
| ▸ | HMGCR | P04035 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7997923 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3980884 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9320884 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL17287304 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3989821 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL17608718 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3840581 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3856545 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL3859291 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR | |
| SCHEMBL9209758 | 1.00 | PTPN7 (0.50) | PTPN7HMGCRRECQLTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2871178-B1 | CATIONIC LIPID | KYOWA KIRIN CO LTD (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | KYOWA KIRIN CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-3162794-B1 | ALKYL SUBSTITUTED AZETIDINES AS CATIONIC LIPID | KYOWA KIRIN CO LTD (JP) | 2020-09-16 | — | — | EP | disclosed |
| EP-3662913-A1 | NUCLEIC-ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Kirin Co., Ltd. (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-10342758-B2 | Cationic lipid | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20180353434-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| US-9913907-B2 | RNAi pharmaceutical composition for suppressing expression of KRAS gene | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-03-13 | — | — | US | disclosed |
| EP-3275448-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9839616-B2 | Lipid nano particles comprising cationic lipid for drug delivery system | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-20170224619-A1 | CATIONIC LIPID | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20040166059-A1 | Cobalamin conjugates useful as imaging and therapeutic agents | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2004-08-26 | — | — | US | disclosed |
| US-20040162240-A1 | Cobalamin conjugates useful as antitumor agents | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2004-08-19 | — | — | US | disclosed |
| EP-1239887-A1 | COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1171162-A2 | COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6284784-B1 | 2-HYDROXYMETHYL DERIVATIVES | GEORGETOWN UNIVERSITY | 2001-09-04 | — | — | US | disclosed |
| WO-2001028595-A1 | COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2000062808-A2 | COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1015427-A1 | SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC | GEORGETOWN UNIVERSITY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5962504-A | ACTIVATOR OF PROTEIN KINASE; ANTICANCER AGENT | GEORGETOWN UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1999012901-A1 | SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC | GEORGETOWN UNIVERSITY (US) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162240-A1 | Cobalamin conjugates useful as antitumor agents | MMAB, SLC19A2, SLC19A1 | PTPN7 4190/4885HMGCR 760/4885RECQL 902/4885 |
| US-20180353434-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLES | FASN, ABHD16A, PHAX | PTPN7 4072/4885HMGCR 733/4885RECQL 1147/4885 |
| US-20170224619-A1 | CATIONIC LIPID | NPC1L1, NPC1, SGMS1 | PTPN7 4069/4885HMGCR 676/4885RECQL 1040/4885 |
| US-10342758-B2 | Cationic lipid | LIPA, LCLAT1, RNASEH1 | PTPN7 4179/4885HMGCR 1119/4885RECQL 555/4885 |
| US-20040166059-A1 | Cobalamin conjugates useful as imaging and therapeutic agents | MMAB, SLC19A1, SLC19A2 | PTPN7 4654/4885HMGCR 673/4885RECQL 1091/4885 |
| US-20200368173-A1 | NUCLEIC ACID-CONTAINING LIPID NANOPARTICLE | LIPA, LIPC, PNLIP | PTPN7 3186/4885HMGCR 530/4885RECQL 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.